DDR-TRK-1 NEW
| Price | $117 | $175 | $268 |
| Package | 1mg | 2mg | 5mg |
| Min. Order: | |
| Supply Ability: | 10g |
| Update Time: | 2024-11-19 |
Product Details
| Product Name: DDR-TRK-1 | CAS No.: 1934246-19-1 |
| Purity: 99.86% | Supply Ability: 10g |
| Release date: 2024/11/19 |
Product Introduction
Bioactivity
| Name | DDR-TRK-1 |
| Description | DDR-TRK-1, a selective discoid domain receptor 1 (DDR1) inhibitor, exhibits an IC50 value of 9.4 nM and also inhibits the TRK family. |
| In vitro | DDR-TRK-1 is a promising candidate with an IC50 value of 9.4 nM relative to DDR1. It exhibited reasonable pharmacokinetic (PK) properties, with an oral bioavailability of 66.8% and a T1/2 value of 1.25 h at a 20 mg/kg oral dose in rats. The area under the concentration-time curve (AUC) value in mice was significantly higher than in rats, indicating good absorption performance in mice. Binding affinity studies of DDR1-IN-3 and DDR1 protein further verified DDR-TRK-1's inhibitory effect on DDR1, showing a binding constant (Kd) value of 4.7 nM[1]. |
| In vivo | DDR-TRK-1 can prevent blm-induced pathological changes in a dose-dependent manner. These results agree with the expression levels of fibrosis markers in the lung tissue, including lysates, including fibronectin and α-smooth muscle actin (SMA). Further analysis also showed that the use of DDR-TRK-1 resulted in a dose-dependent inhibition of hydroxyproline content, a unique amino acid found in collagen. The above data indicate that DDR-TRK-1 has good therapeutic potential for blm-induced pulmonary fibrosis[1]. |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
| Solubility Information | DMSO : 50 mg/mL (101.52 mM) |
| Keywords | DDR-TRK-1 | DDRTRK1 | DDR TRK 1 |
| Inhibitors Related | DDR Inhibitor | Ddr1-In-1 | VU6015929 | DDR1-IN-4 | FGFR1/DDR2 inhibitor 1 | WRG-28 | Sitravatinib | LCB 03-0110 | DDR1-IN-2 | Merestinib | (S)-4-methyl-N-(3-(4-methyl-1H-imidazol-1-yl)-5-(trifluoromethyl)phenyl)-2-(pyrimidin-5-yl)-1,2,3,4-tetrahydroisoquinoline-7-carboxamide |
| Related Compound Libraries | Bioactive Compound Library | Membrane Protein-targeted Compound Library | Tyrosine Kinase Inhibitor Library | Kinase Inhibitor Library | Inhibitor Library | Bioactive Compounds Library Max | Fluorochemical Library |
Company Profile Introduction
Target Molecule Corp. (TargetMol) is a global high-tech enterprise, headquartered in Boston, MA, specializing in chemical and biological research product and service to meet the research needs of global customers.
TargetMol has evolved into one of the biggest global compound library and small molecule suppliers and a customer based on 40+ countries. TargetMol offers over 80 types of compound libraries and a wide range of high-quality research chemicals including inhibitors, activator, natural compounds, peptides, inhibitory antibodies, and novel life-science kits, for laboratory and scientific use. Besides, virtual screening service is also available for customers who would like to conduct the computer-aided drug discovery.
You may like
Recommended supplier
| Product name | Price | Suppliers | Update time | |
|---|---|---|---|---|
| $118.00/1mg |
VIP3Y
|
TargetMol Chemicals Inc.
|
2024-11-19 | |
| $2800.00/100mg |
VIP1Y
|
TargetMol Chemicals Inc.
|
2024-10-22 | |
| $1.00/1g |
VIP1Y
|
Apeloa production Co.,Limited
|
2024-06-05 | |
| $117.00/1mg |
VIP3Y
|
TargetMol Chemicals Inc.
|
2024-11-19 |
United States- Since: 2011-01-07
- Address: 36?Washington?Street, Wellesley?Hills
INQUIRY